Experienced in Hydatidiform Mole

Dr. Sharyn N. Lewin

Gynecologic Oncology | Oncology
Excelcare Medical Associates PA
408 37th St, 
Union City, NJ 
Accepting New Patients
Offers Telehealth
Experienced in Hydatidiform Mole
Excelcare Medical Associates PA
408 37th St, 
Union City, NJ 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Sharyn Lewin is a Gynecologic Oncologist and an Oncologist in Union City, New Jersey. Dr. Lewin is rated as an Experienced provider by MediFind in the treatment of Hydatidiform Mole. Her top areas of expertise are Endometrial Cancer, Ovarian Cancer, Malignant Mixed Mullerian Tumor, Hysterectomy, and Oophorectomy. Dr. Lewin is currently accepting new patients.

Her clinical research consists of co-authoring 55 peer reviewed articles and participating in 6 clinical trials. MediFind looks at clinical research from the past 15 years.

Graduate Institution
University Of Kansas School Of Med (Kc/wich/sal)
Specialties
Gynecologic Oncology
Oncology
Licenses
Obstetrics & Gynecology in NY
Hospital Affiliations
Holy Name Medical Center
Languages Spoken
English
Gender
Female

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
Clover Health
  • INSURANCE PLAN
  • MEDICARE MAPD
EmblemHealth
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • OTHER COMMERCIAL
  • OTHER MEDICARE PART D
Horizon Healthcare
  • EPO
  • POS
Independent Health
  • EPO
  • POS
  • PPO
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
Medicare
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE PART D
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 7 Less Insurance Carriers -

Locations

EXCELCARE MEDICAL ASSOCIATES PA
408 37th St, Union City, NJ 07087
Other Locations
EXCELCARE MEDICAL ASSOCIATES PA
718 Teaneck Rd, Teaneck, NJ 07666

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

6 Clinical Trials

MIRASOL: A Randomized, Open-label, Phase 3 Study of Mirvetuximab Soravtansine vs. Investigator's Choice of Chemotherapy in Platinum-Resistant, Advanced High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancers With High Folate Receptor-Alpha Expression
MIRASOL: A Randomized, Open-label, Phase 3 Study of Mirvetuximab Soravtansine vs. Investigator's Choice of Chemotherapy in Platinum-Resistant, Advanced High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancers With High Folate Receptor-Alpha Expression
Enrollment Status: Completed
Publish Date: August 27, 2025
Intervention Type: Drug
Study Drugs: Mirvetuximab Soravtansine, Paclitaxel, Topotecan, Pegylated liposomal doxorubicin
Study Phase: Phase 3
A Randomized, Double-blind, Phase 3 Comparison of Platinum-based Therapy With TSR-042 and Niraparib Versus Standard of Care Platinum-based Therapy as First-line Treatment of Stage III or IV Nonmucinous Epithelial Ovarian Cancer
A Randomized, Double-blind, Phase 3 Comparison of Platinum-based Therapy With TSR-042 and Niraparib Versus Standard of Care Platinum-based Therapy as First-line Treatment of Stage III or IV Nonmucinous Epithelial Ovarian Cancer
Enrollment Status: Active_not_recruiting
Publish Date: March 13, 2025
Intervention Type: Drug
Study Drugs: Niraparib, Dostarlimab
Study Phase: Phase 3
A Phase 2, Single Arm Study of Mirvetuximab Soravtansine in Recurrent Platinum-Sensitive, High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancers With High Folate Receptor-Alpha Expression (PICCOLO)
A Phase 2, Single Arm Study of Mirvetuximab Soravtansine in Recurrent Platinum-Sensitive, High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancers With High Folate Receptor-Alpha Expression (PICCOLO)
Enrollment Status: Completed
Publish Date: December 20, 2024
Intervention Type: Drug
Study Drug: Mirvetuximab Soravtansine
Study Phase: Phase 2
SORAYA: A Phase 3, Single Arm Study of Mirvetuximab Soravtansine in Platinum-Resistant, Advanced High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancers With High Folate Receptor-Alpha Expression
SORAYA: A Phase 3, Single Arm Study of Mirvetuximab Soravtansine in Platinum-Resistant, Advanced High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancers With High Folate Receptor-Alpha Expression
Enrollment Status: Completed
Publish Date: August 07, 2024
Intervention Type: Drug
Study Drug: Mirvetuximab Soravtansine
Study Phase: Phase 3
A Phase II Study of Abemaciclib in Combination With Letrozole in Advanced, Recurrent or Metastatic Endometroid Endometrial Cancer
A Phase II Study of Abemaciclib in Combination With Letrozole in Advanced, Recurrent or Metastatic Endometroid Endometrial Cancer
Enrollment Status: Active_not_recruiting
Publish Date: December 13, 2023
Intervention Type: Drug
Study Drugs: Abemaciclib, Letrozole
Study Phase: Phase 2
Trial of Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy (HIPEC) in Patients With Primary Peritoneal Cancers and Secondary Peritoneal Cancers From Stomach, Colorectal, Appendiceal, and/or Gynecological Origins
Trial of Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy (HIPEC) in Patients With Primary Peritoneal Cancers and Secondary Peritoneal Cancers From Stomach, Colorectal, Appendiceal, and/or Gynecological Origins
Enrollment Status: Completed
Publish Date: August 03, 2022
Intervention Type: Drug, Device
View 5 Less Clinical Trials

55 Total Publications

The efficacy and safety of mirvetuximab soravtansine in FRα-positive, third-line and later, recurrent platinum-sensitive ovarian cancer: the single-arm phase II PICCOLO trial.
The efficacy and safety of mirvetuximab soravtansine in FRα-positive, third-line and later, recurrent platinum-sensitive ovarian cancer: the single-arm phase II PICCOLO trial.
Journal: Annals of oncology : official journal of the European Society for Medical Oncology
Published: September 27, 2024
Similar Doctors
Advanced in Hydatidiform Mole
Dr. Jeff F. Lin
Gynecologic Oncology | Oncology | Obstetrics and Gynecology
Advanced in Hydatidiform Mole
Dr. Jeff F. Lin
Gynecologic Oncology | Oncology | Obstetrics and Gynecology

Weill Medical College Of Cornell

525 E 68th St, 
New York, NY 
 (3.9 miles away)
212-746-3268
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Jeff Lin is a Gynecologic Oncologist and an Oncologist in New York, New York. Dr. Lin is rated as an Advanced provider by MediFind in the treatment of Hydatidiform Mole. His top areas of expertise are Vaginal Cancer, Endometrial Cancer, Ovarian Cancer, Oophorectomy, and Hysterectomy.

Advanced in Hydatidiform Mole
Dr. Kristen P. Zeligs
Gynecologic Oncology | Oncology | Obstetrics and Gynecology
Advanced in Hydatidiform Mole
Dr. Kristen P. Zeligs
Gynecologic Oncology | Oncology | Obstetrics and Gynecology

Icahn School Of Medicine At Mount Sinai

1 Gustave Levy Place, Mount Sinai Hospital, 
New York, NY 
 (4.0 miles away)
212-241-2232
Languages Spoken:
English
See accepted insurances

Kristen Zeligs is a Gynecologic Oncologist and an Oncologist in New York, New York. Dr. Zeligs is rated as an Advanced provider by MediFind in the treatment of Hydatidiform Mole. Her top areas of expertise are Endometrial Cancer, Malignant Mixed Mullerian Tumor, Cervical Cancer, Hysterectomy, and Oophorectomy.

Experienced in Hydatidiform Mole
Dr. Nadeem R. Abu-Rustum
Gynecologic Oncology | Oncology
Experienced in Hydatidiform Mole
Dr. Nadeem R. Abu-Rustum
Gynecologic Oncology | Oncology

Mskcc Surgery Group

160 E 53rd St, 
New York, NY 
 (3.2 miles away)
212-610-0496
Languages Spoken:
English
See accepted insurances

Nadeem Abu-Rustum is a Gynecologic Oncologist and an Oncologist in New York, New York. Dr. Abu-Rustum is rated as an Elite provider by MediFind in the treatment of Hydatidiform Mole. His top areas of expertise are Endometrial Cancer, Cervical Cancer, Ovarian Cancer, Hysterectomy, and Lymphadenectomy.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Lewin's expertise for a condition
ConditionClose
    View All 11 Advanced Conditions
    View All 31 Experienced Conditions
    Want to save this doctor for later?
    Sign Up
    Is this your doctor?
    Find A Second Opinion
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile